|
1
|
Wynn TA and Ramalingam TR: Mechanisms of
fibrosis: therapeutic translation for fibrotic disease. Nat Med.
18:1028–1040. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lederer DJ and Martinez FJ: Idiopathic
Pulmonary Fibrosis. N Engl J Med. 378:1811–1823. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kendall RT and Feghali-Bostwick CA:
Fibroblasts in fibrosis: Novel roles and mediators. Front
Pharmacol. 5:1232014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
King TE Jr, Schwarz MI, Brown K, Tooze JA,
Colby TV, Waldron JA Jr, Flint A, Thurlbeck W and Cherniack RM:
Idiopathic pulmonary fibrosis: relationship between histopathologic
features and mortality. Am J Respir Crit Care Med. 164:1025–1032.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tang X, Peng R, Phillips JE, Deguzman J,
Ren Y, Apparsundaram S, Luo Q, Bauer CM, Fuentes ME, DeMartino JA,
et al: Assessment of Brd4 inhibition in idiopathic pulmonary
fibrosis lung fibroblasts and in vivo models of lung
fibrosis. Am J Pathol. 183:470–479. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang J, Zhou F, Li Z, Mei H, Wang Y, Ma H,
Shi L, Huang A, Zhang T, Lin Z, et al: Pharmacological targeting of
BET proteins attenuates radiation-induced lung fibrosis. Sci Rep.
8:9982018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yamazaki R, Kasuya Y, Fujita T, Umezawa H,
Yanagihara M, Nakamura H, Yoshino I, Tatsumi K and Murayama T:
Antifibrotic effects of cyclosporine A on TGF-beta1-treated lung
fibroblasts and lungs from bleomycin-treated mice: role of
hypoxia-inducible factor-1alpha. FASEB J. 31:3359–3371. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2−ΔΔCq method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ohkuro M, Kim JD, Kuboi Y, Hayashi Y,
Mizukami H, Kobayashi-Kuramochi H, Muramoto K, Shirato M,
Michikawa-Tanaka F, Moriya J, et al: Calreticulin and integrin
alpha dissociation induces anti-inflammatory programming in animal
models of inflammatory bowel disease. Nat Commun. 9:19822018.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chen J, Bardes EE, Aronow BJ and Jegga AG:
ToppGene Suite for gene list enrichment analysis and candidate gene
prioritization. Nucleic Acids Res. 37:W305–W311. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Subramanian A, Tamayo P, Mootha VK,
Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub
TR, Lander ES, et al: Gene set enrichment analysis: a
knowledge-based approach for interpreting genome-wide expression
profiles. Proc Natl Acad Sci U S A. 102:15545–15550. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Serini G, Bochaton-Piallat ML, Ropraz P,
Geinoz A, Borsi L, Zardi L and Gabbiani G: The fibronectin domain
ED-A is crucial for myofibroblastic phenotype induction by
transforming growth factor-beta1. J Cell Biol. 142:873–881. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sandbo N and Dulin N: Actin cytoskeleton
in myofibroblast differentiation: ultrastructure defining form and
driving function. Transl Res. 158:181–196. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hunninghake GW: Antioxidant therapy for
idiopathic pulmonary fibrosis. N Engl J Med. 353:2285–2287. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Raghu G, Noth I and Martinez F:
N-acetylcysteine for idiopathic pulmonary fibrosis: the door is
still open. Lancet Respir Med. 5:e1–e2. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pierce EM, Carpenter K, Jakubzick C,
Kunkel SL, Flaherty KR, Martinez FJ and Hogaboam CM: Therapeutic
targeting of CC ligand 21 or CC chemokine receptor 7 abrogates
pulmonary fibrosis induced by the adoptive transfer of human
pulmonary fibroblasts to immunodeficient mice. Am J Pathol.
170:1152–1164. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yang X, Chen B, Liu T and Chen X: Reversal
of myofibroblast differentiation: a review. Eur J Pharmacol.
734:83–90. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sieber P, Schäfer A, Lieberherr R, Le Goff
F, Stritt M, Welford WD, Gatfield J, Peter O, Nayler O and Lüthi U:
Novel high-throughput myofibroblast assays identify agonists with
therapeutic potential in pulmonary fibrosis that act via EP2 and
EP4 receptors. PLoS One. 13:e02078722018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Garrison G, Huang SK, Okunishi K, Scott
JP, Kumar Penke LR, Scruggs AM and Peters-Golden M: Reversal of
myofibroblast differentiation by prostaglandin E(2). Am J Respir
Cell Mol Biol. 48:550–558. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Huang SK, Fisher AS, Scruggs AM, White ES,
Hogaboam CM, Richardson BC and Peters-Golden M: Hypermethylation of
PTGER2 confers prostaglandin E2 resistance in fibrotic fibroblasts
from humans and mice. Am J Pathol. 177:2245–2255. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Anathy V, Roberson EC, Guala AS, Godburn
KE, Budd RC and Janssen-Heininger YM: Redox-based regulation of
apoptosis: S-glutathionylation as a regulatory mechanism to control
cell death. Antioxid Redox Signal. 16:496–505. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ono A, Utsugi M, Masubuchi K, Ishizuka T,
Kawata T, Shimizu Y, Hisada T, Hamuro J, Mori M and Dobashi K:
Glutathione redox regulates TGF-beta-induced fibrogenic effects
through Smad3 activation. FEBS Lett. 583:357–362. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
McMillan DH, van der Velden JL, Lahue KG,
Qian X, Schneider RW, Iberg MS, Nolin JD, Abdalla S, Casey DT, Tew
KD, et al: Attenuation of lung fibrosis in mice with a clinically
relevant inhibitor of glutathione-S-transferase π. JCI Insight.
1:e857172016. View Article : Google Scholar
|
|
24
|
Wynes MW, Edelman BL, Kostyk AG, Edwards
MG, Coldren C, Groshong SD, Cosgrove GP, Redente EF, Bamberg A,
Brown KK, et al: Increased cell surface Fas expression is necessary
and sufficient to sensitize lung fibroblasts to Fas
ligation-induced apoptosis: implications for fibroblast
accumulation in idiopathic pulmonary fibrosis. J Immunol.
187:527–537. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gong Y, Wang N, Liu N and Dong H: Lipid
peroxidation and GPX4 inhibition are common causes for
myofibroblast differentiation and ferroptosis. DNA Cell Biol.
38:725–733. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Stratton MS, Haldar SM and McKinsey TA:
BRD4 inhibition for the treatment of pathological organ fibrosis.
F1000Res. 6:10152017. View Article : Google Scholar
|
|
27
|
Sanders YY, Ambalavanan N, Halloran B,
Zhang X, Liu H, Crossman DK, Bray M, Zhang K, Thannickal VJ and
Hagood JS: Altered DNA methylation profile in idiopathic pulmonary
fibrosis. Am J Respir Crit Care Med. 186:525–535. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Davies ER, Haitchi HM, Thatcher TH, Sime
PJ, Kottmann RM, Ganesan A, Packham G, O'Reilly KM and Davies DE:
Spiruchostatin A inhibits proliferation and differentiation of
fibroblasts from patients with pulmonary fibrosis. Am J Respir Cell
Mol Biol. 46:687–694. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tzouvelekis A and Kaminski N: Epigenetics
in idiopathic pulmonary fibrosis. Biochem Cell Biol. 93:159–170.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mullenbrock S, Liu F, Szak S, Hronowski X,
Gao B, Juhasz P, Sun C, Liu M, McLaughlin H, Xiao Q, et al: Systems
analysis of transcriptomic and proteomic profiles identifies novel
regulation of fibrotic programs by miRNAs in pulmonary fibrosis
fibroblasts. Genes (Basel). 9:E5882018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Dakhlallah D, Batte K, Wang Y,
Cantemir-Stone CZ, Yan P, Nuovo G, Mikhail A, Hitchcock CL, Wright
VP, Nana-Sinkam SP, et al: Epigenetic regulation of miR-17-92
contributes to the pathogenesis of pulmonary fibrosis. Am J Respir
Crit Care Med. 187:397–405. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lyu X, Fang W, Cai L, Zheng H, Ye Y, Zhang
L, Li J, Peng H, Cho WC, Wang E, et al: TGFβR2 is a major target of
miR-93 in nasopharyngeal carcinoma aggressiveness. Mol Cancer.
13:512014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Oak SR, Murray L, Herath A, Sleeman M,
Anderson I, Joshi AD, Coelho AL, Flaherty KR, Toews GB, Knight D,
et al: A micro RNA processing defect in rapidly progressing
idiopathic pulmonary fibrosis. PLoS One. 6:e212532011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Liu G, Friggeri A, Yang Y, Milosevic J,
Ding Q, Thannickal VJ, Kaminski N and Abraham E: miR-21 mediates
fibrogenic activation of pulmonary fibroblasts and lung fibrosis. J
Exp Med. 207:1589–1597. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Christmann RB, Wooten A, Sampaio-Barros P,
Borges CL, Carvalho CR, Kairalla RA, Feghali-Bostwick C, Ziemek J,
Mei Y, Goummih S, et al: miR-155 in the progression of lung
fibrosis in systemic sclerosis. Arthritis Res Ther. 18:1552016.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Fu LL, Tian M, Li X, Li JJ, Huang J,
Ouyang L, Zhang Y and Liu B: Inhibition of BET bromodomains as a
therapeutic strategy for cancer drug discovery. Oncotarget.
6:5501–5516. 2015. View Article : Google Scholar : PubMed/NCBI
|
